NCT05162391Completed
Inflammation in Methamphetamine and STIs (IMSTI)
Effects of Methamphetamine Use on Risk Behavior, Systemic and Mucosal Inflammation, and Sexually Transmitted Infection (STI)/HIV Risk Among Men Who Have Sex With Men
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 59 (actual)
- First submitted
- 30 Nov 2021
- Start date
- 31 May 2022
- Primary completion date
- 15 Apr 2026
- Lead sponsor
- University of California, Los Angeles
- Diseases
- HIV
- NCT number
- NCT05162391
What you commit to
- Study type: Interventional
- Participants enrolled: 59
- From 31 May 2022 to the primary completion date, 15 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Reports current treatment for another substance use disorder
- Treatment for gonorrhea and/or chlamydia infection in past 3 months
- Presence of a condition that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Other
- Positive test for opioids, cocaine, and/or hallucinogens
Who the study is looking for
- Cisgender male
- 18 years of age or older
- Understand written and spoken English
- Condomless receptive anal intercourse in past 90 days
- Meet DSM-5 criteria for methamphetamine use disorder
- Positive urine toxicology screen for MA metabolites at study entry
- Negative rectal GC/CT screen (n=20) or Positive rectal GC and/or CT screen (n=20)
- Able to provide written informed consent and willing/able to complete study visits.
Age in the registry: 18 years to - · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA Vine Street Clinic Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.